New International Study Highlights IOP-Lowering Performance of Glaukos iStent inject® Trabecular Micro-Bypass in Standalone Procedure

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that in a study published in Advances in Therapy, 100% of 57 phakic eyes with open-angle glaucoma achieved a ≥ 20% reduction in unmedicated intraocular pressure (IOP) one year after implantation of the iStent inject® Trabecular Mic